Mabion S.A., a Polish biotechnology firm, has signed a letter of intent with French TechDev company Oddifact SAS to evaluate and advance MabionCD20 for potential applications in rare diseases. This collaboration signifies the reactivation of Mabion’s CD20 program through a strategic development approach aimed at exploring new clinical indications.
The partnership leverages Mabion’s extensive expertise in monoclonal antibody development and biologics manufacturing alongside Oddifact’s AI-driven orphan drug identification platform. The goal is to facilitate the registration of MabionCD20 as an innovative treatment for orphan diseases, building on the asset’s prior Phase III clinical trial success.
Originally developed as a biosimilar to MabThera and Rituxan, MabionCD20 has already received two FDA Orphan Drug Designations, reinforcing its potential in rare disease applications. This collaboration reflects Mabion’s strategy to extract additional value from existing assets while expanding beyond traditional CDMO operations through high-value co-development opportunities. The companies plan to finalize a binding Cooperation Agreement by the end of 2026, focusing on regulatory strategies and commercialization activities.
Start your 7-day trial and see what the database can do →
